Skip to main content
Top

Cancer Immunology, Immunotherapy

Issue 9/2005

Content (12 Articles)

Original Article

Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy

Gregory B. Lesinski, Daniel Valentino, Erinn M. Hade, Susie Jones, Cynthia Magro, Abhik Ray Chaudhury, Michael J. Walker, William E. Carson III

Original Article

Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy

Tobias Krüger, Oliver Schoor, Claudia Lemmel, Bjoern Kraemer, Christian Reichle, Jörn Dengjel, Toni Weinschenk, Margret Müller, Jörg Hennenlotter, Arnulf Stenzl, Hans-Georg Rammensee, Stefan Stevanović

Original Article

Role of tumor-derived transforming growth factor-β1 (TGF-β1) in site-dependent tumorigenicity of murine ascitic lymphosarcoma

V. S. Thakur, B. Shankar, S. Chatterjee, S. Premachandran, K. B. Sainis

Original Article

Phase I study of TNFα AutoVaccIne in Patients with metastatic cancer

A. M. Waterston, L. Gumbrell, T. Bratt, S. Waller, J. Gustav-Aspland, C L‘Hermenier, K Bellenger, M Campbell, T Powles, M Highley, M Bower, S. Mouritsen, M. Feldmann, R. C. Coombes

Original Article

Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas

Jose Manuel Cózar, Julia Canton, Miguel Tallada, Angel Concha, Teresa Cabrera, Federico Garrido, Francisco Ruiz-Cabello Osuna

Original Article

Exposure to the electrofusion process can increase the immunogenicity of human cells

Barry D. Hock, Georgina Roberts, Judith L. McKenzie, Prachee Gokhale, Nina Salm, Alexander D. McLellan, Nigel W. Patton, Justin A. Roake

Original Article

Sustained low-level expression of interferon-γ promotes tumor development: potential insights in tumor prevention and tumor immunotherapy

Yu-Fei He, Xiao-Hong Wang, Gui-Mei Zhang, Hong-Tao Chen, Hui Zhang, Zuo-Hua Feng

Original Article

Transforming growth factor-β1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system

Florian Weber, Scott N. Byrne, Shery Le, David A. Brown, Samuel N. Breit, Richard A. Scolyer, Gary M. Halliday

Original Article

Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo

Jia-Hai Ma, Yan-Fang Sui, Jing Ye, Ya-Yu Huang, Zeng-Shan Li, Guang-Sheng Chen, Ping Qu, Hong-Ping Song, Xiu-Min Zhang

Original Article

Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas

Janet M. D. Plate, Aileen E. Plate, Susan Shott, Susan Bograd, Jules E. Harris

Original Article

Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study

J. M. Kerst, A. Bex, H. Mallo, L. Dewit, J. B. A. G. Haanen, W. Boogerd, H. J. Teertstra, G. C. de Gast

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine